0001193125-24-093929.txt : 20240412 0001193125-24-093929.hdr.sgml : 20240412 20240412073631 ACCESSION NUMBER: 0001193125-24-093929 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240411 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240412 DATE AS OF CHANGE: 20240412 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Invivyd, Inc. CENTRAL INDEX KEY: 0001832038 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 851403134 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40703 FILM NUMBER: 24839995 BUSINESS ADDRESS: STREET 1: 1601 TRAPELO ROAD STREET 2: SUITE 178 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 819-0080 MAIL ADDRESS: STREET 1: 1601 TRAPELO ROAD STREET 2: SUITE 178 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Adagio Therapeutics, Inc. DATE OF NAME CHANGE: 20201112 8-K 1 d748852d8k.htm 8-K 8-K
false 0001832038 0001832038 2024-04-11 2024-04-11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 11, 2024

 

 

Invivyd, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-40703   85-1403134

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

1601 Trapelo Road, Suite 178

Waltham, MA

   02451
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (781) 819-0080

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common stock, par value $0.0001 per share   IVVD   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Chief Executive Officer and Director

David Hering, the Chief Executive Officer of Invivyd, Inc. (the “Company”), ceased serving as an executive officer and as the Company’s “principal executive officer”, effective as of April 11, 2024, with his employment terminating on May 11, 2024. The Board of Directors of the Company (the “Board”) is instituting a search for Mr. Hering’s successor as permanent Chief Executive Officer.

Upon Mr. Hering executing a separation agreement, and subject to Mr. Hering agreeing to a release of claims and complying with certain other continuing obligations contained therein, the Company will pay Mr. Hering the amounts owed to him pursuant to Section 5 of that certain Employment Agreement, dated July 5, 2022, by and between the Company and Mr. Hering, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (“SEC”) on July 5, 2022, as amended by that certain First Amendment, dated June 15, 2023, filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023 (as amended, the “Hering Employment Agreement”).

In connection with Mr. Hering ceasing to serve as Chief Executive Officer, Mr. Hering has also resigned from the Board pursuant to the terms of the Hering Employment Agreement. The Board also reduced the size of the Board from nine (9) members to eight (8) members.

Appointment of Jeremy Gowler as Interim Chief Executive Officer

On April 11, 2024, the Board appointed Jeremy Gowler, the Company’s current Chief Operating Officer and Chief Commercial Officer, as the Company’s Interim Chief Executive Officer and designated him as the Company’s “principal executive officer”, effective immediately. Mr. Gowler will remain as the Company’s Chief Operating Officer and Chief Commercial Officer while serving as Interim Chief Executive Officer. In connection with the management transition and until a permanent Chief Executive Officer is named, Mr. Gowler will work in collaboration with an executive committee of the Board led by Marc Elia, the Chairperson of the Board, which committee, along with the Board, will provide oversight and strategic guidance on the business and affairs of the Company.

Mr. Gowler, 47, has served as the Company’s Chief Operating Officer and Chief Commercial Officer since December 2022. Most recently, Mr. Gowler held the role of Global Head of Commercial for the Biopharmaceutical business of Sandoz (a division of Novartis) from April 2020 until his departure in 2022 to join the Company. Mr. Gowler began his career at Novartis in 2002 and progressed through roles of increasing responsibility in the areas of marketing, sales, medical affairs and operations in Canada, the U.S. and in Switzerland until his departure in 2014. He then joined PaxVax, a private equity backed biotechnology company, where he held the role of VP, Global Commercial from 2014 until October 2018. PaxVax was sold to Emergent Biosolutions in 2018, where Mr. Gowler became VP of Global Commercial for Emergent’s vaccine business unit until his departure for Sandoz in March 2020. Mr. Gowler holds a BSc with a double major in Biology and Environmental Studies from the University of Victoria and a Dipl T in Marketing Management from the British Columbia Institute of Technology.

In connection with Mr. Gowler’s appointment as Interim Chief Executive Officer, the Company and Mr. Gowler entered into an amendment (the “Gowler Amendment”) to that certain employment agreement, dated September 17, 2022, between the Company and Mr. Gowler, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 6, 2022 (the “Gowler Employment Agreement”). Pursuant to the Gowler Amendment, the Company will pay Mr. Gowler an additional monthly payment of $5,000 while Mr. Gowler serves as Interim Chief Executive Officer. In addition, for calendar year 2024, Mr. Gowler’s annual bonus will be calculated as follows: (i) for the period during which Mr. Gowler serves only as Chief Operating Officer and Chief Commercial Officer, Mr. Gowler’s target bonus will be forty percent (40%) of Mr. Gowler’s actual base salary for the calendar year 2024; and (ii) for the period during which Mr. Gowler serves as Interim Chief Executive Officer, his target bonus will be fifty-five percent (55%) of an assumed annualized base salary of $525,000 (calculated using Mr. Gowler’s base salary of $465,000 plus the additional amounts payable as Interim Chief Executive Officer on an annualized basis). The Gowler Amendment also provides, among other things, that neither the removal of Mr. Gowler’s Interim Chief Executive Officer title, nor the diminution of or removal of the interim related duties, will constitute grounds for “Good Reason” pursuant to Section 3(e) of the Gowler Employment Agreement.

There are no arrangements or understandings between Mr. Gowler and any other persons pursuant to which Mr. Gowler was appointed as Interim Chief Executive Officer of the Company. There are also no family relationships between Mr. Gowler and any director or executive officer of the Company and Mr. Gowler has no direct or indirect interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The foregoing description of the Gowler Amendment is only a summary and is qualified in its entirety by reference to the complete terms and conditions of the Gowler Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 7.01

Regulation FD Disclosure.

On April 12, 2024, the Company issued a press release announcing changes to its management team. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 7.01.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.		   

Description

10.1    First Amendment to the Employment Agreement of Jeremy Gowler, dated April 11, 2024, by and between Invivyd, Inc. and Jeremy Gowler
99.1    Press Release, dated April 12, 2024
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INVIVYD, INC.
Date: April 12, 2024     By:  

/s/ Jill Andersen

      Jill Andersen
      Chief Legal Officer and Corporate Secretary
 EX-10.1 2 d748852dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

FIRST AMENDMENT TO THE

EMPLOYMENT AGREEMENT OF JEREMY GOWLER

This FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF JEREMY GOWLER (the “Amendment”) is entered into this April 11, 2024 (the “Amendment Effective Date”), by and between JEREMY GOWLER (the “Executive”) and INVIVYD, INC. (the “Company”).

RECITALS

WHEREAS, the Company and Executive have entered into that certain Employment Agreement dated September 17, 2022 (the “Executive Agreement”); and

WHEREAS, the Company desires to continue to employ Executive as its Chief Operating Officer and Chief Commercial Officer of the Company and to employ Executive as its Interim Chief Executive Officer, and Executive desires to accept such employment and to perform the duties to the Company on the terms and conditions hereinafter set forth in this Amendment; and

WHEREAS, the Company and Executive wish to amend the Executive Agreement as set forth in this Amendment.

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other valid consideration, the sufficiency of which is acknowledged, the parties hereto agree as follows:

AGREEMENT

 

1.

Amendment to Section 1(b). Section 1(b) of the Executive Agreement is hereby amended by replacing Section 1(b) in its entirety with the following:

(b) Position and Duties. Executive shall serve as the Chief Operating Officer and Chief Commercial Officer of the Company and shall have such powers and duties as customarily associated with the office of the Chief Operating Officer and Chief Commercial Officer, and as may from time to time be prescribed by the Chief Executive Officer of the Company (the “CEO”) or the Company’s Board of Directors (the “Board”). Executive shall report to the CEO and shall be subject to the direction and control of the CEO and the Board. Nothing in this Agreement shall prohibit Executive from reasonably delegating parts of the responsibilities set forth in or contemplated by this Section 1(b) to other employees of the Company or its subsidiaries.

As of April 11, 2024 (the “Amendment Effective Date”), Executive shall additionally serve as the Interim Chief Executive Officer of the Company and shall have such powers and duties as customarily associated with the office of Interim Chief Executive Officer, and as may from time to time be prescribed by the Board or a designated committee thereof, subject to the direction and control of the Board or a designated committee thereof. In his service as Interim Chief Executive Officer, Executive shall report to the Board or a designated committee thereof.

2.

Amendment to Section 2(a). Section 2(a) of the Executive Agreement is hereby amended by replacing Section 2(a) in its entirety with the following:

(a) Base Salary. The Company will continue to pay Executive, as compensation for the performance of Executive’s duties and obligations hereunder, salary at the rate of $465,000 per year, less applicable deductions. Executive’s salary shall be subject to annual review not later than March 31st of each year for possible increase by the Board or the Compensation Committee of the Board (the “Compensation Committee”), which may be adjusted from time to time. The base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for its executive officers. As of the Amendment Effective Date, and while Executive serves as Interim Chief Executive Officer, Executive shall receive an additional monthly payment of $5,000, less applicable deductions.

 

3.

Amendment to Section 2(c). Section 2(c) of the Executive Agreement is hereby amended by inserting the following sentence immediately following the end of the third sentence in Section 2(c):

Subject to the foregoing, as of the Amendment Effective Date and while Executive serves as Interim Chief Executive Officer, the Target Bonus will be fifty-five percent (55%) of the Base Salary. For the calendar year 2024, the Annual Bonus shall be calculated as follows: (i) for the period during which Executive serves only as Chief Operating Officer and Chief Commercial Officer, the Target Bonus will be forty percent (40%) of Executive’s actual Base Salary for the calendar year 2024; and (ii) for the period during which Executive serves as Interim Chief Executive Officer, the Target Bonus will be fifty-five percent (55%) of an assumed base salary of $525,000.

 

4.

The Company and Executive further agree that this Amendment does not constitute grounds for “Good Reason” pursuant to Section 3(e) of the Executive Agreement, or otherwise constitute any trigger for the Company’s payment of any severance benefits to Executive pursuant to the Executive Agreement. The Company and Executive further agree that Executive’s title of Interim Chief Executive Officer is temporary, and neither the removal of the Interim Chief Executive Officer title, nor the diminution of or removal of the interim related duties, will constitute grounds for “Good Reason” pursuant to Section 3(e) of the Executive Agreement.

5.

Except as modified or amended in this Amendment, no other term or provision of the Executive Agreement is amended or modified in any respect. Executive remains employed “at will.” The Executive Agreement and its exhibits, the Employee Proprietary Information and Inventions Assignment Agreement, and this Amendment, set forth the entire understanding between the parties with regard to the subject matter hereof and supersedes any prior oral discussions or written communications and agreements. This Amendment cannot be modified or amended except in writing signed by Executive and an authorized officer of the Company.

The parties have executed this First Amendment to the Employment Agreement of Jeremy Gowler on the day and year first written above.

 

INVIVYD, INC.

/s/ Marc Elia

Marc Elia
Chairperson of the Board
EXECUTIVE

/s/ Jeremy Gowler

Jeremy Gowler

I hereby acknowledge and reaffirm my obligations pursuant to the Employee Proprietary Information and Inventions Assignment Agreement.

 

/s/ Jeremy Gowler

Jeremy Gowler
Date: April 11, 2024
 EX-99.1 3 d748852dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Invivyd Announces CEO Transition

Jeremy Gowler appointed Interim CEO

WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the company’s Board of Directors has appointed Jeremy Gowler as Interim Chief Executive Officer (CEO), effective immediately, while the Board institutes a search for a permanent CEO. Mr. Gowler succeeds Dave Hering.

“The Invivyd Board of Directors is positioning the company for its next phase of growth,” said Marc Elia, Chairperson. “Invivyd is poised to lead a brand-new paradigm in delivering novel, impactful monoclonal antibody (mAb) therapies for the pre-exposure prophylaxis (PrEP) of COVID-19, and we wish to fully unlock this capability and associated value creation. In the interim, we are pleased to align the day-to-day leadership of the company with Jeremy, who is primarily responsible for our commercial execution, and I personally look forward to partnering with him on the success of the company. With PEMGARDA™, our novel pipeline mAb candidates for COVID PrEP, and our strong balance sheet, we believe we have a highly attractive and undervalued base on which to build a class-leading company in virology. The Board would like to thank Dave for his contributions in bringing the company from the research phase through first emergency use authorization.”

“I am eager to work closely with the Invivyd Board and strengthen engagement with key internal and external stakeholders, while remaining focused on delivering a successful launch of PEMGARDA. Invivyd has tremendous potential to reach and support vulnerable populations and their caregivers with PEMGARDA and beyond,” said Mr. Gowler.

About PEMGARDA

PEMGARDA™ (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab, Invivyd’s investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in a global Phase 2/3 clinical trial for the prevention of COVID-19. PEMGARDA has demonstrated in vitro neutralizing activity in pseudotyped virus-like particle and authentic virus neutralization assays against major SARS-CoV-2 variants, including JN.1, the dominant variant in the U.S. currently according to estimates from the Centers for Disease Control and Prevention. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells.

PEMGARDA (pemivibart) injection (4500 mg), for intravenous use is an investigational mAb that has not been approved, but has been authorized for emergency use by the U.S. FDA under an EUA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2. PEMGARDA is not authorized for use for treatment of COVID-19 or post-exposure prophylaxis of COVID-19. Anaphylaxis has been observed with PEMGARDA and the PEMGARDA Fact Sheet for Healthcare Providers includes a boxed warning for anaphylaxis. The most common adverse events (all grades, incidence ≥2%) observed in participants who have moderate-to-severe immune compromise treated with PEMGARDA included systemic and local infusion-related or hypersensitivity reactions, upper respiratory tract infection, viral infection, influenza-like illness, fatigue, headache, and nausea. For additional information, please see the PEMGARDA full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning.

To support the EUA for PEMGARDA, an immunobridging approach was used to determine if PEMGARDA may be effective for pre-exposure prophylaxis of COVID-19. Immunobridging is based on the serum virus neutralizing titer-efficacy relationships identified with other neutralizing human mAbs against SARS-CoV-2. This includes adintrevimab, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy for other neutralizing human mAbs against SARS-CoV-2 was based on different populations and SARS-CoV-2 variants that are no longer circulating. Additionally, the variability associated with cell-based EC50 value determinations, along with limitations related to pharmacokinetic data and efficacy estimates for the mAbs in prior clinical trials, impact the ability to precisely estimate protective titer ranges.

The emergency use of PEMGARDA is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a commercial-stage company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “could,” “expects,” “intends,” “potential,” “projects,” and “future” or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the anticipated benefits of the company’s management transition; the company’s anticipated next phase of growth, future prospects, and potential value creation; the company’s expectations for the commercial launch of PEMGARDA; the potential of the company to reach and support vulnerable populations and their caregivers; the company’s ongoing research and clinical development efforts; the company’s mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2; the design of the company’s INVYMAB platform approach to facilitate the rapid, serial generation of new mAbs to keep pace with evolving viral threats; the company’s expectation that PEMGARDA is the first mAb in a planned series of innovative, novel, impactful antibody candidates; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company’s forward-looking statements and you should not place undue reliance on the company’s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: potential challenges or disruptions to the business as a result of the company’s management transition; how long the EUA granted by the FDA for PEMGARDA will remain in effect and whether the EUA is revoked or revised by the FDA; the company’s ability to build and maintain sales, marketing and distribution capabilities to successfully commercialize PEMGARDA; changes in expected or existing competition; the timing and progress of the company’s discovery, preclinical and clinical development activities; the uncertainties and timing of the regulatory authorization or approval process, and available development and regulatory pathways for authorization or approval of the company’s product candidates; changes in the regulatory environment; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of PEMGARDA or any other product candidate following regulatory authorization or approval; the predictability of clinical success of the company’s product candidates based on neutralizing activity in preclinical studies; the risk that results of preclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; the company’s reliance on third parties with respect to virus assay creation and product candidate testing and with respect to its clinical trials; variability of results in models used to predict activity against SARS-CoV-2 variants; whether PEMGARDA or any other product candidate is able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; the complexities of manufacturing mAb therapies; the company’s dependence on third parties to manufacture, label, package, store and distribute clinical and commercial supplies of its product candidates; whether the company is able to provide sufficient commercial supply of PEMGARDA to meet market demand; whether the company can obtain and maintain third-party coverage and adequate reimbursement for PEMGARDA or any other product candidate; the company’s ability to leverage its INVYMAB platform approach to facilitate the rapid, serial generation of new mAbs to keep pace with evolving viral threats; any litigation and other proceedings or government investigations relating to the company; the company’s ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC), and in the company’s other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

###

Contacts:

Media Relations

(781) 208-1747

media@invivyd.com

Investor Relations

(781) 208-1747

investors@invivyd.com

EX-101.SCH 4 ivvd-20240411.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 ivvd-20240411_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 6 ivvd-20240411_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
Apr. 11, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001832038
Document Type 8-K
Document Period End Date Apr. 11, 2024
Entity Registrant Name Invivyd, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-40703
Entity Tax Identification Number 85-1403134
Entity Address, Address Line One 1601 Trapelo Road
Entity Address, Address Line Two Suite 178
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code (781)
Local Phone Number 819-0080
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol IVVD
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d748852d8k.htm ivvd-20240411.xsd ivvd-20240411_lab.xml ivvd-20240411_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d748852d8k.htm": { "nsprefix": "ivvd", "nsuri": "http://invivyd.com/20240411", "dts": { "inline": { "local": [ "d748852d8k.htm" ] }, "schema": { "local": [ "ivvd-20240411.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "ivvd-20240411_lab.xml" ] }, "presentationLink": { "local": [ "ivvd-20240411_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-04-11_to_2024-04-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d748852d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-04-11_to_2024-04-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d748852d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://invivyd.com//20240411/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001193125-24-093929-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-093929-xbrl.zip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end XML 18 d748852d8k_htm.xml IDEA: XBRL DOCUMENT 0001832038 2024-04-11 2024-04-11 false 0001832038 8-K 2024-04-11 Invivyd, Inc. DE 001-40703 85-1403134 1601 Trapelo Road Suite 178 Waltham MA 02451 (781) 819-0080 false false false false Common stock, par value $0.0001 per share IVVD NASDAQ true false